Hansa Biopharma AB, (Hansa), pioneer in enzyme technology for rare immunological conditions, announces the completion of enrollment in its phase 2 study evaluating safety, tolerability and efficacy of imlifidase in patients with active and chronic active antibody mediated rejection (AMR) episodes. A first data read out is expected in the second half of 2022, as previously guided.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!